Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable revenue growth from Tyvyt in the next three years as Tyvyt has more indications approved.
Price cuts for PD-1 end up leading to higher prices, lifting Innovent’s gross margin.
Mazdutide approval turns out to be later than expected, which will dampen our base case revenue forecast from 2026 onwards.
|
Metric
|
01801
|
01093
|
01099
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 10.53 | 6.71 |
Price/Book Value | 4.90 | 2.00 | 0.79 |
Price/Sales | 8.40 | 2.10 | 0.10 |
Price/Cash Flow | — | 9.17 | 3.27 |
|
Metric
|
01801
|
01093
|
01099
|
|---|---|---|---|
Quick Ratio | 2.59 | 2.32 | 1.05 |
Current Ratio | 3.00 | 2.63 | 1.39 |
Interest Coverage | −15.20 | 276.31 | 7.35 |
|
Metric
|
01801
|
01093
|
01099
|
|---|---|---|---|
Return on Assets (Normalized) | −2.75% | 14.29% | 4.43% |
Return on Equity (Normalized) | −5.12% | 19.78% | 24.34% |
Return on Invested Capital (Normalized) | −5.63% | 17.91% | 9.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kzyxlqtny | Jghbb | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Djjdhxxm | Plrcvwz | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xwznzmjvd | Kmqyqf | $114.0 Bil | |||
| Moderna Inc
MRNA
| Chdlbtqq | Snsp | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vkzcwjnhq | Xjtmhf | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Tfbyptlym | Zjgkt | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Kdkbwhys | Cymqm | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vbttdtdgj | Wjvhfp | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Kyclbzgg | Nbqj | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mprbcfkvpw | Mvqlbsp | $11.6 Bil |
